Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
|ClinicalTrials.gov Identifier: NCT01630967|
Recruitment Status : Unknown
Verified June 2012 by Kim Chi, British Columbia Cancer Agency.
Recruitment status was: Not yet recruiting
First Posted : June 28, 2012
Last Update Posted : June 28, 2012
British Columbia Cancer Agency
Information provided by (Responsible Party):
Kim Chi, British Columbia Cancer Agency
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Publications of Results:
Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083. Epub 2011 Jul 23.